179898-87-4

Basic information

• Product Name: tert-butyl 2,2-dimethyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate
• Synonyms: tert-butyl 2,2-dimethyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate;tert-butyl 3,4-dihydro-2,2-diMethyl-4-oxoquinoline-1(2H)-carboxylate;2,2-Dimethyl-4-oxo-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester
• CAS NO: 179898-87-4
• Molecular Formula: C16H21 N O3
• Molecular Weight: 275.34
• Mol File: 179898-87-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 370.5±22.0 °C(Predicted)
• Appearance: /
• Density: 1.103±0.06 g/cm3(Predicted)
• PKA: -1.79±0.40(Predicted)
• CAS DataBase Reference: tert-butyl 2,2-dimethyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2,2-dimethyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate(179898-87-4)
• EPA Substance Registry System: tert-butyl 2,2-dimethyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate(179898-87-4)

Safety Data

• Hazardous Substances Data: 179898-87-4(Hazardous Substances Data)

Usage

Description

Tert-butyl 2,2-dimethyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate is a chemical compound with the molecular formula C17H23NO3. It is a yellow crystalline powder known for its anti-inflammatory and antioxidant properties, as well as its potential as an anti-cancer agent. tert-butyl 2,2-dimethyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate is primarily used as an intermediate in the synthesis of pharmaceutical compounds.

Uses

Used in Pharmaceutical Industry:
Tert-butyl 2,2-dimethyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate is used as an intermediate in the synthesis of pharmaceutical compounds for its potential therapeutic applications.
Used in Drug Development:
Tert-butyl 2,2-dimethyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate is used as a potential candidate for the development of new drugs for various diseases due to its anti-inflammatory and antioxidant properties.
Used in Cancer Research:
Tert-butyl 2,2-dimethyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate is used as a potential anti-cancer agent, and further research is needed to fully understand its mechanisms of action and potential therapeutic applications.

Upstream product

• 300808-64-4 4-Hydroxy-2,2-dimethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester 
• 7722-84-1 dihydrogen peroxide 
• 179898-89-6 1-tert-butoxycarbonyl-1,2-dihydro-2,2-dimethylquinoline 
• 14465-61-3 2,2-dimethyl-1,2-dihydroquinoline 
• 7471-09-2 3-methyl-3-phenylamino-1-butyne 

Downstream Products

• 179899-03-7 (R/S)-3-ethyl-1,2,3,4-tetrahydro-2,2-dimethylquinoline 
• 179898-88-5 1,2,3,4-tetrahydro-2,2,3-trimethylquinoline 
• 1028304-66-6 2,2,3,3-Tetramethyl-4-oxo-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester 
• 132588-91-1 1,2,3,4-tetrahydro-2,2-dimethylquinolin-4-one 
• 20364-30-1 2,2-dimethyl-1,2,3,4-tetrahydroquinoline 
• 179899-22-0 7-amino-1,2,3,4-tetrahydro-2,2-dimethylquinoline 
• 201541-36-8 1,2,3,4-tetrahydro-2,2-dimethyl-7-nitroquinoline 
• 179899-02-6 (R/S)-3-ethyl-1,2,3,4-tetrahydro-2,2-dimethyl-4-quinolinone 

Relevant articles and documents

Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2- dihydropyridono[5,6-g]quinolines

A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR- mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure - activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.

STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS

Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.